Who are Ordaos's investors?

Ordaos's investors include Citta Capital, Route 66 Ventures, StartX, SVE Capital, IAG Capital Partners, Middleland Capital.

How much funding has Ordaos raised?

Ordaos has disclosed $16.8M raised across 6 rounds.

Where is Ordaos headquartered?

Ordaos is headquartered in New York, US.

Ordaos

New York, US · Founded 2019 · Delaware corporation · 24 employees on LinkedIn · 6 known investors

Find your way into Ordaos

Paths you didn't know you had: your email and LinkedIn already hold routes to the Ordaos team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Ordaōs uses AI and deep learning through its Design Engine to design novel mini-proteins and protein binders such as nanobodies for drug discovery. The company serves pharmaceutical and biologics researchers, combining generative machine-learning models with wet-lab protein expression and characterization.

AI & Machine Learning Biotech Deep Tech

Founders & leadership

David Longo Co-Founder & Chief Executive OfficerDavid Longo studied rumor propagation and network analysis during his undergraduate education and previously founded a music technology startup. He holds degrees from Harvard and Stanford, and is co-founder and CEO of Ordaōs, an AI-driven protein design company serving drug discovery.

Matthias Denecke Chief Technology OfficerMatthias Denecke holds a PhD in Computer Science from Karlsruhe and has spent 15+ years building production machine-learning systems across pharmaceutical, automotive, and enterprise sectors, including roles at Pfizer (semantic search for deviation reports), Ford (embedded conversational AI), and Ordaos (founding engineer to CTO), where he led platform and ML infrastructure for protein design. His published research covers reinforcement learning, natural language processing, and protein development, with two patents from NTT Communication Science Labs.

Victor Bustos VP of Pre-clinical R&DVictor Bustos is VP of Pre-clinical R&D at Ordaōs. He brings over 20 years of protein engineering experience, including leadership of high-throughput cell-free expression and biophysics platforms, work with computational protein design methods, and prior roles as a Group Leader at Rockefeller University in the laboratory of Nobel Laureate Paul Greengard where he led drug discovery in neurodegenerative diseases, as well as experience founding an Alzheimer's diagnostics startup.

Scott HornerNamed on SEC filing

Board

Benjamin Britt Board directorManaging Partner at Route 66 Ventures

Ulo PalmBoard director

James Ramey Board directorManaging Director at Middleland Capital

Investors · 6

Citta Capitallisted by Citta CapitalPalo Altovia Jim Mao · inferred

How we know: funding news · Not right? Tell us

Route 66 Ventureslisted by Route 66 VenturesAlexandria · $500K – $4M

How we know: Route 66 Ventures's portfolio page · Not right? Tell us

StartXlisted by StartXStanford · $10K – $1M

How we know: StartX's portfolio page · Not right? Tell us

SVE Capitallisted by SVE CapitalPalo Alto

IAG Capital PartnersreportedCharleston

How we know: funding news · Not right? Tell us

Middleland CapitalreportedArlington

How we know: funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$16.8M disclosed across 6 rounds · 2022–2025

▶$337.7KraisedApr 2025 · 3 investors · Biotechnology

Rule 506(b)